ROMERIO ALESSIO

Italia, A., Romerio, A., Lami, F., Sarcinelli, G., Lenoci, M., Galli, M., et al. (2025). Functional impact of Toll-like Receptor 4 (TLR4) modulation in lung fibrosis-associated fibroblasts. Intervento presentato a: ABCD 2025. The Biennial Congress of the Italian Association of Cell Biology and Differentiation, Paestum, Italy. Dettaglio

Italia, A., Franco, A., Shaik, M., Romerio, A., Lami, F., Lovisa, S., et al. (2025). Study on the impact of Toll-like Receptor 4 (TLR4) modulation in rare inflammatory-fibrotic diseases. In Convegno Nazionale della Divisione di Chimica dei Sistemi Biologici 2025. Trieste 18-20 Giugno 2025. Book of abstracts (pp.68-68). Dettaglio

Shirey, K., Romerio, A., Shaik, M., Leake, D., Palmer, C., Skupinska, N., et al. (2025). Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection. INNATE IMMUNITY, 31 [10.1177/17534259241313201]. Dettaglio

Sainz-Mejias, M., Ma, C., Hou, Y., Jurado-Martin, I., Romerio, A., Franco, A., et al. (2025). Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy against Pseudomonas aeruginosa Challenge. ACS INFECTIOUS DISEASES, 11(4), 894-904 [10.1021/acsinfecdis.4c00932]. Dettaglio

Franco, A., Aladailleh, Z., Romerio, A., Italia, A., Lami, F., Shaik, M., et al. (2025). Towards more efficient synthetic immunomodulators: biological characterization and mechanism of action of monosaccharide-derived TLR4 agonists. RSC MEDICINAL CHEMISTRY, 16(5), 2261-2269 [10.1039/D4MD00950A]. Dettaglio